

Chemicals/Finland, November 6, 2023 Company update

Earnings wait for higher orders

Exel has taken actions to recover earnings. In our view wind power orders should drive at least some growth next year, but order outlook uncertainty continues to limit upside.


Actions support bottom line, but order outlook is still soft Exel Q3 revenue declined 39% y/y, which led to an adj. EBIT of EUR -1.2m. Exel has cut costs and was also able to generate a positive cash flow of EUR 1.2m, however on the negative side Q4 orders may stay rather soft as larger orders have been further postponed due to cool demand in many industries. Destocking has been a big theme for a while, but in our view Exel's industries' long-term drivers are intact and hence we would expect at least modest growth across customer accounts next year if markets stabilize. We cut our Q4 revenue estimate by EUR 5m and make more downward revisions to our FY '24 estimates.

Wind power orders to drive growth next year

Wind power generated EUR 25-30m revenue in previous years, whereas we estimate it to make only some EUR 10m this year. In our view wind power could add another EUR 10m in revenue next year, assuming the industry order outlook somewhat normalizes. Comparison top line figures will be soft for almost all customer industries next year, and the US unit reorientation alone will help achieve EUR 3m in annual cost savings. The assetlight business model shouldn't require much capex especially in the short run when there's still a lot of existing capacity to be utilized. Exel will however soon provide more detail on the kind of modifications its current plant network needs. We believe there to be not much need for growth capex at this point, and single production line updates shouldn't be too expensive as we understand such lines often cost well below EUR 1m each.

EBIT will recover once orders start to pick up

We estimate wind power to drive double-digit growth next year. In our view EUR 115m top line going forward should support 6% EBIT margins, considering the cost measures Exel has implemented and still finds. Exel is valued some 9x EV/EBIT, which we don't view too expensive as an EBIT of below EUR 7m would still be quite modest relative to potential. We don't see margin potential as such as the key issue going forward, but rather order recovery is required before upside can materialize. Our new TP is EUR 2.7 (3.0) as we retain our HOLD rating.



■ BUY □ HOLD ■ SELL

+358 44 430 9071

KEY FIGU	RES										
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR	
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20	
2022	137.0	3.0	2.2%	9.4	0.18	30.1	0.7	31.4	14.6	0.20	
2023E	101.6	-4.8	-4.7%	0.9	-0.68	-3.9	0.6	-13.2	2.8	0.00	
2024E	113.8	6.8	6.0%	3.0	0.27	9.8	0.5	8.8	9.3	0.15	
2025E	121.7	8.5	7.0%	5.3	0.45	6.0	0.5	6.6	16.8	0.20	
Market cap	o, EURm		32 G	earing 2023E,	0/0		5, %	35.2			
Net debt 2	023E, EURm		31 Pi	rice/book 2023	BE		1.6 CAGR	sales 2022-	25, %	-3.9	
Enterprise	value, EURm		63 D	ividend yield 2	.023E, %		0.0 ROE 2023E, %				
Total asset	s 2023E, EURn	n	93 Ta	ax rate 2023E,	0/0			-8.4			
Goodwill 2	023E, EURm		13 Ec	quity ratio 202	23E, %			0.0			

Telephone



Chemicals/Finland, November 6, 2023 Company update

Estimates and valuation

Exel Composites	2019	2020	2021	Q1'22	Q2'22	Q3'22	Q4'22	2022	Q1'23	Q2'23	Q3'23	Q4'23e	2023e
Buildings and infrastructure	23.5	23.5	32.9	7.7	8.9	7.8	8.1	32.5	7.8	6.5	5.7	7.0	26.9
Equipment and other industries	18.6	19.5	23.4	7.4	5.9	5.6	4.3	23.1	5.6	5.0	4.0	3.8	18.4
Wind power	23.6	28.1	32.1	6.8	6.5	8.0	5.5	26.8	1.5	2.3	2.1	4.8	10.7
Machinery and electrical	14.4	15.5	17.6	4.3	5.3	5.0	5.2	19.7	4.6	4.1	3.4	4.6	16.7
Transportation	13.1	10.2	10.2	3.1	7.2	3.7	3.3	17.4	4.2	3.7	3.1	2.9	13.9
Defense	2.3	5.3	8.7	2.1	1.6	2.0	1.9	7.5	2.9	2.6	1.4	1.7	8.5
Telecommunications	8.2	6.5	9.5	2.8	2.8	1.7	2.6	10.0	2.2	1.3	8.0	2.1	6.4
Revenue	103.8	108.6	134.4	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6
y/y change, %	7 %	5 %	24 %	10 %	14 %	1 %	-15 %	2 %	-16 %	-33 %	-39 %	-13 %	-26 %
Adjusted EBIT	7.2	9.7	6.0	2.2	3.1	1.8	0.9	8.0	0.0	0.1	-1.2	0.7	-0.4
EBIT	5.1	9.4	3.7	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8
-margin, %	6.9 %	8.9 %	4.5 %	6.4 %	8.2 %	5.4 %	3.0 %	5.9 %	0.0 %	0.3 %	-5.9 %	2.6 %	-0.4 %
-margin (reported), %	4.9 %	8.7 %	2.8 %	0.1 %	7.9 %	5.0 %	-5.5 %	2.2 %	-1.0 %	-1.0 %	-3.2 %	-13.4 %	-4.7 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	462		15.6x	10.5x		29.0x	17.7x	-8.0 %	4.6 %	7.1 %
Hexcel	5133	19.0x	17.2x	14.4x	31.6x	26.8x	20.9x	11.4 %	12.8 %	14.9 %
Avient	2845	8.0x	9.2x	8.3x	11.7x	14.3x	12.4x	11.9 %	10.4 %	11.6 %
SGL Carbon	734	6.0x	7.4x	5.0x	9.9x	11.7x	7.8x	9.9 %	7.1 %	10.2 %
TPI Composites	96	13.1x		10.0x			178.6x	-1.6 %	-7.1 %	0.2 %
Gurit Holding	368	13.5x	11.3x	8.2x	22.6x	18.8x	12.1x	4.5 %	4.8 %	6.8 %
Peer Group Average	1606	11.9x	12.1x	9.4x	18.9x	20.1x	41.6x	4.7 %	5.4 %	8.4 %
Peer Group Median	598	13.1x	11.3x	9.2x	17.2x	18.8x	15.0x	7.2 %	6.0 %	8.6 %
Exel Composites (Evli est.)	32	9.3x	31.7x	4.7x	31.4x	-13.2x	8.8x	2.2 %	-4.7 %	6.0 %
Exel Composites prem./disc. to peer mea	lian	-29 %	180 %	-48 %	83 %	-170 %	-41 %	-69 %	-179 %	-30 %

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

Chemicals/Finland, November 6, 2023 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	2.67 PV of Free Cash Flow	61 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	9.45 PV of Horizon value	84 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	253.8 Unconsolidated equity	0 Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	10.4 Marketable securities	17 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	8.6 Debt - dividend	-50 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	58.0 Value of stock	112 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCE valuation ELID	2022	2022E	2024E	2025E	2026E	2027E	2028E	2029E	2020E	2021E	2032E	Horizon
DCF valuation, EURm		2023E	2024E						2030E	2031E		
Net sales	137	102	114	122	128	130	133	136	138	141	143	145
Sales growth, %	2.0	<i>-25.9</i>	12.0	7.0	5.0	2.0	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	3	-5	7	9	10	14	15	16	16	16	16	17
Operating income margin, %	2.2	-4.7	6.0	7.0	8.0	10.5	11.0	11.5	11.5	11.5	11.5	11.5
+ Depreciation+amort.	7	7	6	5	5	5	5	4	4	4	4	
EBITDA	10	2	13	14	15	18	19	20	20	21	21	
- Paid taxes	-1	-1	-2	-2	-3	-3	-4	-4	-4	-4	-4	
- Change in NWC	3	5	-2	-1	-1	0	0	0	0	0	0	
NWC / Sales, %	10.3	8.7	9.4	9.7	10.0	10.1	10.2	10.3	10.4	10.5	10.5	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-3	-3	-4	-4	-4	-4	-4	-4	-4	-4	-4	
opCAPEX / Sales, %	2.4	3.0	3.8	3.5	3.4	3.1	3.1	3.1	3.1	3.1	3.0	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	9	3	5	7	8	11	11	12	12	12	12	177
= Discounted FCFF		3	4	6	6	8	7	7	7	6	6	84
		•	•		•	•	•	•		•		
= DFCF min WACC		3	4	6	6	8	8	7	7	6	6	94
= DFCF max WACC		3	4	6	6	8	7	7	6	6	6	75

Chemicals/Finland, November 6, 2023 Company update

INTERIM FIGURES

EVALUECTIMATES FUR	202201	202202	202202	202204	2022	202201	202202	202202	2022045	20225	20245	20255
EVLI ESTIMATES, EURm	2022Q1	202202	2022Q3	2022Q4	2022	2023Q1	2023Q2	2023Q3	2023Q4E	2023E	2024E	2025E
Net sales	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
EBITDA	1.8	4.8	3.6	0.0	10.1	1.5	1.5	1.1	-2.1	2.0	12.7	14.0
EBITDA margin (%)	5.2	12.5	10.5	0.0	7.4	5.3	5.7	5.6	-7.9	2.0	11.1	11.5
EBIT	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
EBIT margin (%)	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0
Net financial items	0.5	1.9	1.6	-3.4	0.6	-1.2	-0.4	0.2	-0.3	-1.7	-1.6	-1.5
Pre-tax profit	0.5	4.9	3.3	-5.1	3.6	-1.5	-0.7	-0.4	-3.9	-6.5	5.2	7.1
Tax	-0.6	-0.9	-1.2	1.2	-1.5	-0.6	-0.2	-0.2	-0.5	-1.6	-2.0	-1.8
Tax rate (%)	111.4	19.3	35.6	24.3	40.4	-43.8	-36.3	-48.2	-12.8	-24.7	38.3	25.0
Net profit	-0.1	4.0	2.1	-3.9	2.1	-2.1	-0.9	-0.6	-4.4	-8.1	3.2	5.3
EPS	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	-0.05	-0.37	-0.68	0.27	0.45
EPS adjusted (diluted no. of shares)	-0.01	0.33	0.18	-0.33	0.18	-0.18	-0.08	-0.05	-0.37	-0.68	0.27	0.45
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.00	0.15	0.20
SALES, EURm												
Exel Composites	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
Total	34.2	38.1	33.8	31.0	137.0	28.8	25.4	20.5	26.8	101.6	113.8	121.7
SALES GROWTH, Y/Y %												
Exel Composites	10.3	13.5	1.2	-15.1	2.0	-15.7	-33.3	-39.2	-13.5	-25.9	12.0	7.0
Total	10.3	13.5	1.2	-15.1	2.0	-15.7	-33.3	-39.2	-13.5	-25.9	12.0	7.0
EBIT, EURm												
Exel Composites	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
Total	0.0	3.0	1.7	-1.7	3.0	-0.3	-0.2	-0.7	-3.6	-4.8	6.8	8.5
EBIT margin, %												
Exel Composites	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0
Total	0.1	7.9	5.0	-5.5	2.2	-1.0	-1.0	-3.2	-13.4	-4.7	6.0	7.0

Chemicals/Finland, November 6, 2023 Company update

INCOME STATEMENT, EURm	2018	2019	2020	2021	2022	2023E	2024E	2025E
Sales	96.6	103.8	108.6	134.4	137.0	101.6	113.8	121.7
Sales growth (%)	11.9	7.5	4.6	23.7	2.0	-25.9	12.0	7.0
EBITDA	7.7	10.7	15.3	11.9	10.1	2.0	12.7	14.0
EBITDA margin (%)	8.0	10.3	14.1	8.9	7.4	2.0	11.1	11.5
Depreciation	-5.5	-5.6	-5.8	-8.2	-7.1	-6.8	-5.9	-5.5
EBITA	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
EBIT margin (%)	2.3	4.9	8.7	2.8	2.2	-4.7	6.0	7.0
Reported EBIT	2.2	5.1	9.4	3.7	3.0	-4.8	6.8	8.5
EBIT margin (reported) (%)	2.3	4.9	8.7	2.8	2.2	-4.7	6.0	7.0
Net financials	-0.5	-1.2	-2.3	0.4	0.6	-1.7	-1.6	-1.5
Pre-tax profit	1.7	3.9	7.1	4.2	3.6	-6.5	5.2	7.1
Taxes	-1.3	-1.5	-1.7	-2.5	-1.5	-1.6	-2.0	-1.8
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	0.4	2.4	5.4	1.7	2.1	-8.1	3.2	5.3
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	21	23	30	34	31	28	26	25
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	5	3	3	2	2	2	2
Inventory	15	17	16	24	23	17	19	21
Receivables	20	20	21	26	24	18	20	22
Liquid funds	5	7	12	16	17	13	14	15
Total assets	79	85	97	118	113	93	97	99
Liabilities								
Shareholder's equity	26	26	29	31	30	20	23	27
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	3	4	2	2	1	2	2	2
Deferred taxes	0	0	0	0	1	1	1	1
Interest bearing debt	30	32	40	50	46	43	41	38
Non-interest bearing current liabilities	18	21	24	32	26	19	22	23
Other interest-free debt	2	2	2	3	9	9	9	9
Total liabilities	79	85	97	118	113	93	97	99
CASH FLOW, EURm								
+ EBITDA	8	11	15	12	10	2	13	14
- Net financial items	0	-1	-2	0	1	-2	-2	-1
- Taxes	-2	-2	-2	-3	-1	-2	-2	-2
- Increase in Net Working Capital	-4	1	3	-5	3	5	-2	-1
+/- Other	0	0	0	0	0	0	0	0
= Cash flow from operations	1	8	13	5	13	4	7	10
- Capex	-10	-8	-13	-11	-3	-3	-4	-4
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	-9	1	0	-6	9	1		5
+/- New issues/buybacks	0	0	-1	3	-1	0	0	0
- Paid dividend	-4 9	-2	-2 7	-2 9	-2 _	-2	0 -1	-2
+/- Other	-3	3 2	, 5	9 4	-5 2	-3 -4	- I 2	-3 1
Change in cash	-3	2	5	4	2	-4	2	I

Chemicals/Finland, November 6, 2023 Company update

78		2021	2022	2023E	2024E	2025E
78	88	94	64	32	32	32
29	30	36	30	31	28	25
107	118	131	94	63	60	57
104	109	134	137	102	114	122
11	15	12	10	2	13	14
5	9	4	3	-5	7	9
4	7	4	4	-6	5	7
2	5	2	2	-8		5
26		31	30			27
1.0	11	1.0	0.7	0.6	0.5	0.5
						4.0
						6.6
						6.6
						5.9
						8.1
						6.0
						6.0
						1.2
						4.1
						6.7
						10.7
						1.2
0.0	0.0	0.0	0.0	-4.0	10.0	6.1
						11,897
						11,897
						0.45
						0.81
						0.45
						2.24
						0.20
					55.3	44.9
	2.7		3.7	0.0	5.6	7.5
0.9	0.6	-6.5	14.6	2.8	9.3	16.8
9.2	19.5	5.5	7.0	-32.1	15.0	21.3
8.6	14.4	5.1	4.0	-8.4	9.0	11.3
16.3	14.9	17.8	17.1	17.1	17.1	17.1
19.2	19.2	19.6	17.8	18.0	17.9	17.9
20.2	22.0	23.8	19.1	19.1	19.1	19.1
14.1	11.2	12.7	10.3	8.7	9.4	9.7
7.3	11.9	8.2	2.4	3.0	3.8	3.5
7.3	11.9	8.2	2.4	3.0	3.8	3.5
						5.0
	0.1	-0.4	0.9	1.6	0.4	0.5
0.3	0.1 2.0	-0.4 3.0		1.6 15.8	0.4 2.2	0.5 1.8
0.3 2.7	2.0	3.0	2.9	15.8	2.2	1.8
0.3						
	11,897 11,897 11,897 11,897 0.20 0.70 0.06 2.21 0.18 89.2 2.7 0.9 9.2 8.6	11	111 15 12 5 9 4 4 7 4 2 5 2 26 29 31 10 1.1 1.0 10.0 7.7 10.9 21.0 12.5 34.9 21.0 12.5 34.9 12.9 8.8 27.2 32.5 52.9 -26.0 110.9 179.1 -15.3 32.5 16.4 57.0 3.0 3.1 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <	11 15 12 10 5 9 4 3 4 7 4 4 2 5 2 2 26 29 31 30 1.0 1.1 1.0 1.1 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.7 1.0 0.9 0.3 1.4 1.4 1.2.5 3.4.9 3.1.4 3.4.9 3.1.4 1.2.9 3.8.8 2.7.2 7.4 32.5 52.9 -26.0 10.2 10.2 11.0 11.2 0.3 11.3 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 3.1 3.0 0.0 0	111 15 12 10 2 5 9 4 3 -5 4 7 4 4 -6 2 5 2 2 -8 26 29 31 30 20 100 1.1 1.0 0.7 0.6 10.0 7.7 10.9 9.3 31.7 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 21.0 12.5 34.9 31.4 -13.2 32.5 52.9 -26.0 10.2 19.5 32.5 <	111 15 12 10 2 13 5 9 4 3 -5 7 4 7 4 4 -6 5 2 5 2 2 -8 3 26 29 31 30 20 23 1.0 1.1 1.0 0.7 0.6 0.5 10.0 7.7 10.9 9.3 31.7 4.7 21.0 12.5 34.9 31.4 -13.2 8.8 21.0 12.5 34.9 31.4 -13.2 8.8 21.0 12.5 34.9 31.4 -13.2 8.8 21.0 12.5 34.9 31.4 -13.2 8.8 21.0 12.5 34.9 31.4 -13.2 8.8 21.0 12.5 34.9 31.4 -13.2 8.8 32.5 52.9 -26.0 10.2 19.5 12.4

Chemicals/Finland, November 6, 2023 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	0/0
Erikoissijoitusrahasto Aktia Mikro Markka	762,984	2.037	6.4%
OP-Finland Small Firms Fund	752,993	2.010	6.3%
Ilmarinen Mutual Pension Insurance	496,547	1.326	4.2%
Phoebus Fund	420,000	1.121	3.5%
Säästöpankki Pienyhtiöt	288,710	0.771	2.4%
Sumato Oy	231,821	0.619	1.9%
Nelimarkka Heikki Antero	213,545	0.570	1.8%
Veritas Pension Insurance Company Ltd.	199,946	0.534	1.7%
Suutarinen Timo	160,000	0.427	1.3%
Säästöpankki Kotimaa	132,680	0.354	1.1%
Ten largest	3,659,226	9.770	31%
Residual	8,237,617	21.994	69%
Total	11,896,843	31.765	100%

EARNINGS CALENDAR	
February 16, 2024	FY 2023 Results
April 25, 2024	Q1 report
August 15, 2024	Q2 report
October 31, 2024	Q3 report
OTHER EVENTS	
November 13, 2023	CMD

CEO: Paul Sohlberg Mäkituvantie 5 01510 Vantaa
CFO: Mikko Rummukainen Tel: +358 20 7541 200
IR: Sanna Ahvenniemi

Chemicals/Finland, November 6, 2023 Company update

DEFINITIONS

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes— income taxes + minority interest Number of shares
P/BV	DPS
Price per share Shareholders' equity + taxed provisions per share	Dividend for the financial period per share
Market cap	OCF (Operating cash flow)
Price per share * Number of shares	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments
EV (Enterprise value)	FCF (Free cash flow)
Market cap + net debt + minority interest at market value – share of associated companies at market value	Operating cash flow – operative CAPEX – acquisitions + divestments
EV/Sales	FCF yield, %
Enterprise value Sales	Free cash flow Market cap
EV/EBITDA	Operative CAPEX/sales
Enterprise value Earnings before interest, tax, depreciation and amortization	Capital expenditure – divestments – acquisitions Sales
EV/EBIT	Net working capital
Enterprise value Operating profit	Current assets – current liabilities
Net debt	Capital employed/Share
Interest bearing debt – financial assets	Total assets – non-interest bearing debt Number of shares
Total assets	Gearing
Balance sheet total	Net debt Equity
Div yield, %	Debt/Equity, %
Dividend per share Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, %	Equity ratio, %
Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans
ROCE, %	CAGR, %
Profit before extraordinary items + interest expenses+ other financial costs Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, November 6, 2023
Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [6.11.2023, 9:10]. This report has been published on [6.11.2023, 9:30].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

EVLI EQUITY RESEARCH

EXEL COMPOSITES

Chemicals/Finland, November 6, 2023 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, November 6, 2023 Company update

Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
_			

Structured Investments Equity Research

Heikki Savijoki	+358 9 4766 9726	Arttu Heikura	+358 40 082 8098
Aki Lakkisto	+358 9 4766 9123	Joonas Ilvonen Jerker Salokivi	+358 44 430 9071 +358 9 4766 9149
		Jerker Salokivi	+336 9 47 00 9 149

Evli Investment Solutions

Johannes Asuja +358 9 4766 9205



EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000